PMA device
Atellica IM Total PSA II (tPSAII)
Siemens Healthcare Diagnostics, Inc. · Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF, Class III) · First FDA decision Dec 3, 2025, newest Aug 26, 2026Prostate cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "Atellica IM"
MAUDE reports
2,244
Brand "Atellica IM", since 2015
PubMed studies
71
Mentioning "Atellica IM"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Atellica IM Total PSA II (tPSAII)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Atellica IM Total PSA II (tPSAII)PMA supplement
P240021-S001 · Decided Aug 26, 2026 · 180 days after receipt · Normal 180 Day Track
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Prostate Specific AntigenNational determinationOn the books190.31Updated Oct 1, 2026
- Prostate Specific Antigen (Inclusion of ICD-9-CM Code 600.01 for BPH with Urine Obstruction)Coding analysisReview closedCAG-00232NUpdated Sep 15, 2026
- Prostate Specific Antigen (Addition of ICD-9-CM 600.00, Hypertrophy (benign) of Prostate Without Urinary Obstruction, as a covered indication)Coding analysisReview closedCAG-00326NUpdated Sep 15, 2026
- Prostate Cancer Detection with IsoPSA®Local determinationIn effectL39284CGS Administrators, LLCUpdated Oct 30, 2026
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- Cryosurgical Salvage Therapy for Recurrent Prostate CancerNational analysisReview closedCAG-00064NUpdated Sep 14, 2026
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Atellica IM", any status and sponsor, newest update first.
No registered device study names "Atellica IM".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Atellica IM", and for the whole product code for context.
This brand
2,244 reports: 2,229 malfunction, 15 injury, 0 death
Whole product code MTF
390 reports: 373 malfunction, 17 injury, 0 death
Newest reports for this brand
Siemens Healthcare Diagnostics, Inc.
1219913-2026-00202 · Received Oct 30, 2026 · Event dated Oct 27, 2026
Device type: Immunoassay Method, Troponin Subunit (MMI)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Atellica IM"[tiab]. The summary above synthesizes these.
- Vitamin B12 reference intervals.
Andersen SL, Hansen AB, Hindersson P, et al. · Dan Med J · 2023
- Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays.
Ashrafzadeh-Kian S, Figdore D, Larson B, et al. · Clin Chim Acta · 2024Comparative Study
- Evaluation of Siemens Atellica AMH assay and comparison with Roche, Beckman and Ansh Labs.
Shang E, Agustin H, Lee JKY, et al. · Clin Biochem · 2025Comparative Study, Evaluation Study
- Hook effect although rare, still exists.
Napoli G, Leggeri S, Lombardi C, et al. · Clin Biochem · 2025Case Reports
- Performance evaluation of Siemens Atellica enhanced estradiol assay.
Macias-Muñoz L, Filella X, Augé JM, et al. · Adv Lab Med · 2020
- Biological variation estimates for serum neurofilament light chain in healthy subjects.
Carobene A, Maiese K, Abou-Diwan C, et al. · Clin Chim Acta · 2023
- Standardization of two SARS-CoV-2 serology assays to the WHO 20/136 human standard reference material.
Freeman J, Conklin J · J Virol Methods · 2022Research Support, Non-U.S. Gov't
- Clinical Laboratory Validation Study of a High Sensitivity Troponin I Assay on a POCT (Point of Care Testing) Device.
Pitta FG, Leme AC, Gomes SR, et al. · Glob Heart · 2024Validation Study
- Concordance of Three Automated Procalcitonin Immunoassays at Medical Decision Points.
Cho HW, Kim SH, Cho Y, et al. · Ann Lab Med · 2021
- Analytical performance of the Enhanced Liver Fibrosis (ELF) Test on the Atellica IM Analyzer.
Palladino A, Gee M, Shalhoub V, et al. · Clin Chim Acta · 2023
- Establishment of CA19-9 reference intervals in an apparently healthy adult population in Singapore.
Lee JMY, Teo P, Lam LCW · Ann Clin Biochem · 2024
- Analytical performance comparing siemens whole blood point of care Atellica VTLi to the central laboratory plasma Atellica IM high-sensitivity cardiac troponin I assays.
Xiong-Hang K, Schulz K, Sandoval Y, et al. · Clin Biochem · 2023
Other devices of this type
Also filed under product code MTF.
- Elecsys total PSA, total PSA CalSet IIRoche Diagnostics Corp. · PMA 2023
- ARCHITECT Total PSA, Alinity i Total PSAAbbott Laboratories · PMA 2023
- Access Hybritech PSABeckman Coulter, Inc. · PMA 2024
- Dimension Vista Tpsa AssaySiemens Healthcare Diagnostics · PMA 2016
- Advia Centaur Psa AssaySiemens Healthcare Diagnostics · PMA 2017
- Axsym Total PsaAbbott Laboratories · PMA 2011
- Abbott Architect Total PsaAbbott Laboratories · PMA 2011
- Immulite/Immulite 1000/IMMULITE 2000/IMMULITE 2500 Psa & 3RD Generation PsaSiemens Healthcare Diagnostics, Inc. · PMA 2010
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.